ACTION EQOL STUDY

行动情商研究

• 批准号: 7281652
• 负责人: Kevin Alan Schulman
• 金额: $ 17.52万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7281652
• 关键词: Adherence; Bicycling; Caring; Class; Congestive Heart Failure; Control Groups; Cost Savings; Drops; Economics; Effectiveness; End Point; Enrollment; Exercise; Exercise Tolerance; Genetic Crossing Over; Grant; Guidelines; Heart; Heart Rate; Home environment; Hospitalization; Incidence; Intervention; Life; Living Costs; Measures; New York; Outcome; Patient Education; Patients; Population; Quality of life; Quality-Adjusted Life Years; Randomized; Rate; Resources; Safety; Sample Size; Societies; Standards of Weights and Measures; Time; Time Study; Training; Upper arm; Walking; base; cost; cost effectiveness; desire; follow-up; health related quality of life; improved; mortality

DESCRIPTION (provided by applicant): The primary aim of the ACTION Trial is to determine the long-term safety and effectiveness of exercise training for New York Heart Association Classes II-IV congestive heart failure patients in addition to standard of care versus a strategy of standard care alone. The secondary objective is to determine the incidence and significance of exercise-related complications, the effect on exercise tolerance and quality of life, and the cost-effectiveness of training. The exercise training will include 36 facility-based training sessions followed by home-based exercise and interval facility sessions. Training will be at 60-70% of heart rate reserve. Patients randomized to the training arm will train by either walking or bicycle ergometers. Treadmills or exercise bicycles will be provided to training patients by the coordinating center, if desired. Effectiveness will be defined as the primary combined endpoint of all-cause mortality and all-cause hospitalizations. The expected annual baseline rate is 30% for the control group. The expected non-adherence and drop-out rate is 35% the first year and 15% annually thereafter, with a cross-over rate of 5% per year. The regional center team and the coordinating center will implement multiple strategies to improve adherence in patients in the training arm. Using these assumptions, a total sample size of 3000 subjects will be required to detect a 20% reduction in the primary outcome with an alpha level of 0.05 and a power greater than 80%. If the non-adherence and drop-out rate decrease to 30% in the first year and 12.5% annually thereafter, the power to detect a 20% difference is greater than 90%. The primary analysis will be based on intent-to-treat. The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation.

描述（由申请人提供）：